openPR Logo
Press release

Investigation announced for Investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM)

08-21-2021 02:23 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares over potential securities laws violations.

An investigation for investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares over potential securities laws violations.

An investigation was announced over potential securities laws violations by Axsome Therapeutics, Inc. in connection with certain financial statements.

Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Axsome Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

New York based Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) disclosed on August 9, 2021, that the FDA had found deficiencies with its New Drug Application (NDA) for AXS-05. The Company claimed it was attempting to determine the nature of the deficiencies, but that this announcement may delay the approval of AXS-05.

Shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) declined $74.10 per share on June 28, 2021, to as low as $19.38 per share on August 19, 2021.

Those who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) here

News-ID: 2362529 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Axsome

Smoking Cessation and Nicotine Addiction Pipeline Analysis 2025 by DelveInsight …
DelveInsight's, "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2025," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. DelveInsight's analysis shows that the Smoking Cessation and Nicotine Addiction pipeline involves over 5
Axsome Therapeutics, Inc. (NASDAQ: AXSM) Long Term Investor Notice: Lawsuit agai …
An investor in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) filed a lawsuit against certain directors of Axsome Therapeutics, Inc. over alleged breaches of fiduciary duties. Investors who are current long term investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The lawsuit against certain directors comes after a lawsuit was filed against Axsome Therapeutics, Inc.
Investigation announced for NASDAQ: AXSM Investors over possible Wrongdoing at A …
An investigation was announced for clong-term investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) concerning potential breaches of fiduciary duties by certain directors and officers of Axsome Therapeutics, Inc. Investors who are current long term investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on July 12, 2022 coming up in Lawsuit for Investors in Axsome Therapeut …
A deadline is coming up on July 12, 2022 in the lawsuit filed for certain investors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) over alleged securities laws violations by Axsome Therapeutics, Inc. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and there are strict and short deadlines running. Deadline: July 12, 2022. NASDAQ: AXSM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Lawsuit filed for Investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM …
An investor, who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Axsome Therapeutics, Inc. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and for certain investors are short and strict deadlines running. Deadline: July 12, 2022. NASDAQ: AXSM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. New
Investigation announced for Long-Term Investors in Axsome Therapeutics, Inc. (NA …
Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Axsome Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders. New York based Axsome Therapeutics,